Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea.
OBJECTIVE
To examine the feasibility, efficacy, safety, and acceptability of medical abortion among rural and urban women up to 56 days of pregnancy in the Democratic People's Republic of Korea.


METHODS
A total of 199 women (rural n=95, urban n=104) recruited from 2 rural and 2 urban reproductive health clinics received 200mg of oral mifepristone followed 2 days later by 400 microg of sublingual misoprostol. The women's abortion status and satisfaction level were determined 2 weeks later.


RESULTS
Overall complete abortion occurred in 96.0% of the women; there was no statistically significant difference between the groups (rural 95.8%, 95% confidence interval [CI], 89.6-98.8; urban 96.2%, 95% CI, 90.4-98.9). The 2 groups reported similar adverse effects. In total, 90.5% of rural and 88.5% of urban participants were satisfied or very satisfied with the method.


CONCLUSIONS
The high efficacy and acceptability of medical abortion among rural and urban women suggest that medical abortion is a safe alternative to surgical abortion and can be scaled up to other reproductive health clinics in both rural and urban areas of the Democratic People's Republic of Korea, provided that there is appropriate training and supervision.
Tran
Nguyen Toan
NT
International Planned Parenthood Federation, East Southeast Asia and Oceania Regional Office (IPPF ESEAOR), 50450 Kuala Lumpur, Malaysia. ttran@ippf.org
Jang
Myong Chon
MC
Choe
Yong Su
YS
Ko
Won Suk
WS
Pyo
Hae Suk
HS
Kim
Ok Suk
OS
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000028:Abortion, Induced / Q000379:methods*; D000284:Administration, Oral; D000286:Administration, Sublingual; D000328:Adult; D056911:Democratic People's Republic of Korea; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017060:Patient Satisfaction; D010865:Pilot Projects; D011247:Pregnancy; D019035:Rural Health Services; D019037:Urban Health Services
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone